1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Pancreatic Cancer -Pipeline Insights, 2016

Pancreatic Cancer -Pipeline Insights, 2016

  • February 2016
  • -
  • Delve Insight
  • -
  • 563 pages

Summary

DelveInsight’s, “Pancreatic Cancer -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 103 pipeline drugs that fall under the category of Pancreatic Cancer.

Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis. Among the pipeline agents NewLink Genetics Corporation’s algenpantucel-L is expected to be the frontrunner amongst all other drugs. The therapeutic candidate has also received fast Track and orphan drug designations from the FDA and is expected to launch in both the resectable and unresectable locally-advanced settings.

The report also provides a comparative analysis of therapeutics based on the molecule type, route of administration, etc. It also gives insights of other activities such as, agreements, joint ventures, partnerships, acquisitions and mergers.

Scope:

-The new report, provides a Pancreatic Cancer Landscape across the globe
-The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
-Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
-Coverage of the Pancreatic Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
-The report reviews key players involved in the therapeutics development for Pancreatic Cancer and also provide company profiling
-Pipeline products coverage based on various stages of development from NDA filings to discovery.
-Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Reasons to Buy

-Complete Pipeline intelligence and complete understanding over therapeutics development for Pancreatic Cancer
-Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
-Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
-Developing strategic initiatives to support your drug development activities.
-Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
-Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
-Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Pancreatic Cancer -Pipeline Insights, 2016
Table of Contents:

- Pancreatic Cancer Overview
- Pancreatic Cancer Types:
- Epidemiology:
- Market Scenario:
- Pipeline Therapeutics
- An Overview of Pipeline Products for Pancreatic Cancer
- Therapeutics under Development by Companies
- Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Discontinued Products
- Dormant Products
- Companies involved in Therapeutics Development
- Appendix
- Methodology
- Consulting Services
- Disclaimer
- Report Purchase Options
- About DelveInsight
- Contact Us

List of Tables:

- Table 1: Number of Products Under Development for Pancreatic Cancer 2016
- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed), 2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I and IND), 2016
- Table 6: Phase 0 stage Products, 2016
- Table 7: Discovery and Pre-clinical Stage Products, 2016
- Table 8: Assessment by Monotherapy Products, 2016
- Table 9: Assessment by Route Of Administration, 2016
- Table 10: Assessment by Stage and Route Of Administration, 2016
- Table 11: Assessment by Molecule Type, 2016
- Table 12: Assessment by Stage and Molecule Type, 2016
- Table 13: Discontinued Products, 2016
- Table 14: Dormant Products, 2016
- Table 15: Companies Involved in Therapeutic Development, 2016

List of Figures:

- Figure 1: Number of Products under Development for Pancreatic Cancer, 2016
- Figure 2: Late Stage Products (Filed and Phase III), 2016
- Figure 3: Mid Stage Products (Phase II), 2016
- Figure 4: Early Stage Products (Phase I and IND), 2016
- Figure 5: Discovery and Pre-clinical Stage Products, 2016
- Figure 6: Assessment by Monotherapy Products, 2016
- Figure 7: Assessment by Combination Products, 2016
- Figure 8: Assessment by Route of Administration, 2016
- Figure 9: Assessment by Stage and Route of Administration, 2016
- Figure 10: Assessment by Molecule Type, 2016
- Figure 11: Assessment by Stage and Molecule Type, 2016


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.